William Raj Sellers, M.D.

Affiliations: 
Novartis, Basel, Basel-Stadt, France 
 Dana-Farber Cancer Institute and Harvard Medical School, USA 
 Broad Institute - Cancer Program 
Area:
oncology
Google:
"William Sellers"
Mean distance: 19.98 (cluster 51)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Chang L, Jung NY, Atari A, et al. (2024) Author Correction: Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities. Nature Genetics
Chang L, Jung NY, Atari A, et al. (2023) Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities. Nature Genetics
Tiedt R, King FJ, Stamm C, et al. (2023) Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors. Cell Reports. 42: 112297
Bondeson DP, Mullin-Bernstein Z, Oliver S, et al. (2022) Systematic profiling of conditional degron tag technologies for target validation studies. Nature Communications. 13: 5495
Cantor SB, Sellers WR, Pathania S, et al. (2022) David Livingston (1941-2021). Molecular Cell. 82: 4-7
Ito T, Young MJ, Li R, et al. (2021) Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers. Nature Genetics
LaMarche MJ, Acker MG, Argintaru A, et al. (2020) Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer. Journal of Medicinal Chemistry
Palmer AC, Plana D, Gao H, et al. (2020) A proof of concept for biomarker-guided targeted therapy against ovarian cancer based on patient-derived tumor xenografts. Cancer Research
Nusinow DP, Szpyt J, Ghandi M, et al. (2020) Quantitative Proteomics of the Cancer Cell Line Encyclopedia. Cell. 180: 387-402.e16
Cleary JM, Raghavan S, Li YY, et al. (2020) Therapeutic targeting of extracellular FGFR2 activating deletions in intrahepatic cholangiocarcinoma. Journal of Clinical Oncology. 38: 567-567
See more...